Pain Targeting Zalicus focuses on pain therapeutics with clinical-stage candidates Z160 and Z944, presenting selling opportunities to pharma partners seeking neuropathic or inflammatory pain solutions.

Collaborations Existing revenue-generating collaborations with large pharma indicate receptivity to external partnerships; leverage to propose co-development, licensing, or milestone-based deals for additional candidates or discovery technologies.

Ion Channel Expertise Specialization in selective ion channel modulators and high-throughput screening can complement partners’ discovery programs, enabling joint ventures or technology licensing for pain, inflammation, oncology, or infectious disease pipelines.

Financial Footing With modest revenue and substantial funding, Zalicus may be open to strategic partnerships or upfront payments in exchange for rights to assets, platforms, or collaboration-backed pipelines that mitigate risk for buyers.

Scale & Synergy Nearby/overlap with larger biotech ecosystems and Epirus merge history suggests potential for integration or asset leasing opportunities, enabling buyers to access nimble development capabilities without duplicating internal infrastructure.